GlassScriptPhysician profile
David Phillip Theis
NPI 1104147453
$60,923.49
in general payments reported to CMS, 2019-2025
35 companies · $3,924 in 2025
The $3,924 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $381 · 2021: $63.51 · 2022: $1,565 · 2023: $6,407 · 2024: $3,265 · 2025: $3,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,473 · Honoraria: $3,950 · Education: $106 · Travel and Lodging: $67.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,473.36 |
| Honoraria | $3,950.00 |
| Education | $105.64 |
| Travel and Lodging | $67.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,226.75 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Novartis Pharmaceuticals Corporation | $21,475.12 | 2019-2025 | |
| Horizon Therapeutics Plc | $7,272.21 | 2019-2023 | Krystexxa |
| Amgen INC. | $1,713.22 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Ucb, INC. | $1,119.23 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $995.85 | 2021-2025 | Saphnelo |
| Pfizer INC. | $843.86 | 2019-2025 | |
| Glaxosmithkline, LLC. | $546.63 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $381.33 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Sobi, INC | $348.82 | 2022-2025 | |
| Sandoz INC. | $316.92 | 2024-2025 | Hyrimoz, Jubbonti |
| Genentech USA, INC. | $187.54 | 2019-2024 | Actemra |
| Lilly USA, LLC | $185.16 | 2019-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $181.88 | 2022-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $122.12 | 2024-2025 | Opsumit, Uptravi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $121.89 | 2020-2025 | Acthar |
| Celltrion USA INC. | $104.06 | 2023-2024 | Vegzelma, Yuflyma |
| E.R. Squibb & Sons, L.L.C. | $100.93 | 2019-2023 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.92 | 2020-2024 | Cyltezo |
| Radius Health, INC. | $88.35 | 2023-2024 | Tymlos |
| Scilex Pharmaceuticals INC. | $64.61 | 2024-2025 | |
| Octapharma USA, INC. | $62.02 | 2022 | |
| Fresenius Kabi USA, LLC | $43.71 | 2023-2025 | Idacio |
| Alexion Pharmaceuticals, INC. | $41.80 | 2020-2025 | Strensiq |
| Kyowa Kirin, INC. | $41.51 | 2023-2024 | Crysvita |
| Ferring Pharmaceuticals INC. | $33.14 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $32.30 | 2019 | |
| Genzyme Corporation | $31.36 | 2025 | |
| Biocon Biologics INC | $25.39 | 2024 | Hulio |
| Organon LLC | $23.89 | 2025 | Hadlima |
| Regeneron Healthcare Solutions, INC. | $23.10 | 2019 | |
| Mylan Institutional INC. | $22.54 | 2023 | Hulio |
| Aurinia Pharma U.S., INC. | $18.04 | 2022 | |
| Gilead Sciences, INC. | $17.14 | 2019 | |
| Merck Sharp & Dohme LLC | $15.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Theis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.